Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as .alpha..sub.1 -adrenergic receptor antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 12, 1999
Grant Date -
N/A
app pub date -
Jun 5, 1996
filing date -
Jun 9, 1995
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Compounds of Formula I: ##STR1## where R.sup.5 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## and the pharmaceutically acceptable salts and N-oxides thereof, are .alpha..sub.1 -adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully